Advancing the Science of DE Technologies

The significant improvements in primary patency and target lesion revascularization rates associated with drug-eluting therapies are impacting the decisions of endovascular specialists. Staying on top of these rapid advancements takes established clinical leadership and a commitment to researching and developing innovative therapies that can make a difference in patients’ lives. 

Dr. Miguel Montero-Baker discusses why drug-eluting stent technology is important in SFA interventions.

“We’ve now realized that we need a drug effect to avoid intimal hyperplasia….So we're on the right path. Using drugs at this day and age is exactly what we should be doing with probably all our interventions in the femoral popliteal segment.”

Miguel Montero-Baker, MD
Baylor St. Luke’s Medical Center | Houston, TX

Proven Polymer-Based Technology

Boston Scientific’s drug-eluting therapies leverage a biocompatible, fluorinated polymer with over eight years of commercial use that has been implanted in more than 10 million patients.1

Dr. Robert Lookstein discusses the need to refine drug-eluting technologies in order to improve patency rates.

“It's very, very clear that we're going to need pharmacokinetics to be refined in order to offer improvement in patency, so controlled drug delivery over a longer time frame is clearly a step in the right direction.”

Robert Lookstein, MD
Mount Sinai Medical Center | New York, NY

Antiproliferative Therapies in the SFA

Learn how the biological environment, mechanical challenges and timing of disease progression impact treatment of the SFA and how antiproliferative therapies help reduce the risk of restenosis that happens after implantation.

Dr. Jay Kokate discusses the challenges of treating the SFA